Theriva Biologics Inc (TOVX)

Currency in USD
0.4239
-0.0092(-2.12%)
Closed·
After Hours
0.4250+0.0011(+0.26%)
·
TOVX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TOVX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.40730.4470
52 wk Range
0.40207.1500
Key Statistics
Prev. Close
0.4239
Open
0.447
Day's Range
0.4073-0.447
52 wk Range
0.402-7.15
Volume
313.01K
Average Volume (3m)
1.52M
1-Year Change
-92.12%
Book Value / Share
5.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TOVX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.0000
Upside
+1,551.33%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Theriva Biologics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Theriva Biologics Inc Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d’Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Compare TOVX to Peers and Sector

Metrics to compare
TOVX
Peers
Sector
Relationship
P/E Ratio
−0.2x−3.7x−0.5x
PEG Ratio
0.000.010.00
Price/Book
0.2x2.8x2.6x
Price / LTM Sales
-158.4x3.3x
Upside (Analyst Target)
-181.7%43.5%
Fair Value Upside
Unlock−0.5%6.3%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.0000
(+1,551.33% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-1.55 / -4.19
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TOVX Income Statement

People Also Watch

36.81
EXEL
-1.21%
0.415
ADIL
-8.79%
2.86
INMB
+11.33%
0.3699
VXRT
+3.96%
0.701
PMN
-8.48%

FAQ

What Stock Exchange Does Theriva Biologics Trade On?

Theriva Biologics is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Theriva Biologics?

The stock symbol for Theriva Biologics is "TOVX."

What Is the Theriva Biologics Market Cap?

As of today, Theriva Biologics market cap is 3.84M.

What Is Theriva Biologics's Earnings Per Share (TTM)?

The Theriva Biologics EPS (TTM) is -13.25.

From a Technical Analysis Perspective, Is TOVX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Theriva Biologics Stock Split?

Theriva Biologics has split 5 times.

How Many Employees Does Theriva Biologics Have?

Theriva Biologics has 21 employees.

What is the current trading status of Theriva Biologics (TOVX)?

As of 05 Aug 2025, Theriva Biologics (TOVX) is trading at a price of 0.42, with a previous close of 0.42. The stock has fluctuated within a day range of 0.41 to 0.45, while its 52-week range spans from 0.40 to 7.15.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.